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ABSTRACT: 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not stem 
cell injections improve the quality of life in patients with cardiopathy.  
 
STUDY DESIGN: Review of three randomized controlled trial (RCT) articles.  All articles were 
published between 2012 – 2017 and were all printed in the English language. 
 
DATA SOURCES:  All three RCT articles were found through PubMed. 
 
OUTCOMES MEASURED:  One of the outcomes measured in each of the articles were 
improvement in quality of life in patients with cardiopathy.  Among the three review articles, 
quality of life was measured using either the Kansas City Cardiomyopathy Questionnaire 
(KCCQ) and/or the Minnesota Living with Heart Failure Questionnaire (MLHFQ).  
Questionnaires were given to patients at either three, six, and/or twelve months after stem cell or 
visually matched placebo injections.  Higher scores for MLHFQ indicated a decrease in quality 
of life.  Whereas, higher scores in the KCCQ indicated improvement in the quality of life. 
 
RESULTS: All three studies used in this selective EBM review reported improvement in the 
quality of life at 3, 6, and/or 12-month assessment periods.  Hare et al. study reported a p-value 
of 0.05 and 0.0167 versus baseline for the MLHFQ and KCCQ respectively.  Similarly, the 
Hamshere et al. study also reported that a combination of G-CSF with IC BMC demonstrated an 
improvement the quality of life and reported a significant p-value of 0.005 at the one year 
assessment period. Improvement in quality of life was also reported in the Hare et al. study.  A p-
value of 0.009 was reported for autologous stem cell injections.  
 
CONCLUSIONS: The three RCT used in this EBM review concluded that stem cell injections 
improved cardiac function resulting in the improvement of the quality of life in patients with 
cardiopathy. 
 
KEY WORDS: cardiopathy, stem cell, stem cell injections, quality of life 
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INTRODUCTION 
 According to the CDC in 2015, cardiopathy is the leading cause of death in both genders 
and among most ethnicities in the United States.1,2  Cardiopathy is a broad term that is defined as 
any disease of the heart and includes but is not limited to heart failure, cardiomyopathies, 
arrhythmias or valvular diseases.  Since cardiopathy encompasses a vast variety of heart 
diseases, this evidence-based medicine (EBM) review will focus on patients with heart failure. 
Heart failure (HF) is a progressive condition where the heart is unable to pump enough 
blood to meet the body’s demand for oxygen.3  Heart failure can be either left-sided, right-sided 
or both.  Some of the most common leading causes of heart failure are coronary artery disease 
(CAD), hypertension and myocardial infarction.3  It is known that after a myocardial infarction, 
cardiac cells die and the formation of scar tissue replaces the cardiac myocytes resulting in 
decrease heart function.4  In order to compensate for the decrease of function, the heart 
undergoes remodeling which leads to heart failure.4   
 Approximately 5.7 million patients in the United States have heart failure and it has been 
projected that 8 million patients will be diagnosed with heart failure by 2030.5  According to the 
CDC in 2009, heart failure contributed to about one in nine deaths in the United States.6  The 
estimated annual cost of heart failure is $30.7 billion dollars and this total includes the cost of 
health services, medications, and missed days from work.6  The exact number of healthcare visits 
for heart failure annually is unknown as heart failure visits are accounted for in heart disease 
visits.7 
Stem cells are multipotent cells and can be isolated from many organs such as the 
umbilicus, bone marrow and pancreases.4  This EBM review will focus on the mesenchymal 
stem cells (MSC) originating from the umbilical cord and bone marrow as well as granulocyte 
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colony-stimulating factors (G-CSF).8  Under trauma or stressful events, stem cells enter the cell 
cycle and more cells are generated. Historically, it has been argued that unlike other organs, the 
heart does not self-renew after injuries because the heart lacked stem cells.4  However, with the 
discovery of stem cell niches in an adult heart, this theory was refuted.9  Even with the presence 
of stem cells, the heart fails to regenerate because the heart is composed of very little stem cells.9  
MacLellan stated that the heart consists of very little stem cells because these immature stem 
cells lack the ability to fully contract.9  In order to properly pump blood throughout the body, the 
heart must be able to contract with maximum capability and therefore, is composed of very little 
immature stem cells.9  The limited amount of cardiac stem cells resulted in the proposal of stem 
cell injection in cardiopathy patients. 
Stem cell injections are costly and the average cost of a single treatment for autologous 
stem cell is $7694.00 and $6038.00 for allogeneic cells.10  Current treatment of heart failure 
includes medications from classes of angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin II receptor blockers (ARBs), beta-blockers (BB), calcium channel blockers (CCB), 
diuretics and ionotropic agents such as digoxin, dobutamine, and dopamine.5,11  Other treatments 
include sodium restriction in the diet and daily physical activities.5  These current treatments are 
effective in supportive treatment and help decline the progression of heart failure.  However, 
these treatment options do not improve cardiac function like stem cell injections.12  This 
systematic review will evaluate the improvement of the quality of life in patients with 
cardiopathy who received stem cell injections. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not stem cell 
injections improved the quality of life in patients with cardiopathy. 
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METHODS 
 The criteria used for the selection of studies in this selective EBM centered on 
populations, interventions, comparisons, and outcomes.  The population studied were patients 
older than eighteen years and diagnosed with heart failure (Table 1).  The interventions were an 
injection of allogenic UC-MSC, allogenic and autologous bone marrow-derived stem cells, and 
granulocyte colony-stimulating factor (G-CSF) in the treatment groups.  The controlled group 
received visually matched peripheral placebo injections.  Comparison of improvement in the 
quality of life was made between patients that received stem cell or placebo injections.  The 
outcomes were measured with either the Kansas City Cardiomyopathy (KCCQ) or Minnesota 
Living with Heart Failure Questionnaire (MLHFQ) at either three, six, or twelve months. 
 The research articles for this EBM review were selected based on similar inclusion 
criteria and the questionnaire used to measured improvement in the quality of life.   All 
randomized controlled trial (RCT) articles were found through PubMed with a key word search 
consisting of “stem cells”, “heart failure”, “cardiopathy”, “quality of life”, “mesenchymal stroma 
cells” and “bone marrow stem cells”.  All three RCT articles were published in peer-reviewed 
journals, after the year 2007, and in the English language.  The summary of statistics used to 
report the data in all three RCTs were p-values and mean change from baseline. 
Table 1 – Demographics and Characteristics of Included Studies 
Study Type # 
pts 
Age 
(yrs) 
Inclusion criteria Exclusion criteria W/
D 
Interventions 
Barol
ucci, 
2017 
(1) 
RTC 30 18-
75 
Chronic HFrEF 
w/ NYHA 
classification I to 
II and LVEF ≤ 
40% 
End-stage HFrEF, 
recurrent MI, 
uncontrolled V. 
tachycardia, malignant 
disease with life 
expectancy < 1 yr, 
hematologic disease, 
recent cerebrovascular 
disease, serum creatinine 
0 Intravenous 
infusion of 
allogenic UC-
MSCs or 
placebo. 
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> 2.26, atrial fibrillation 
w/o optimal HR control 
Hams
here, 
2015 
(2) 
RTC 60 54-
57 
Diagnosis of non-
ischemic DMC 
w/no secondary 
cause, LVEF of 
40%, symptoms 
classed as NYHA 
II or greater 
Less than 18 years old. 5 Placebo 
(saline), 
peripheral G-
CSF, peripheral 
G-CSF and IC 
serum, and 
peripheral G-
CSF and IC 
BMC.  
Hare, 
2012 
(3) 
RTC 31 21-
90 
Chronic 
ischemia, LV 
dysfunction 
secondary to MI, 
severe 
hypokinesis, 21 
to 90 years old, 
LV ejection, EF 
less than 50%, 
eligibility for 
cardiac 
catheterization 
within 5 to 10 
weeks 
Noncardiac condition 
limiting life expectancy 
to > 1 year, GFR 
>50mL/min, serious 
radiographic contrast 
allergy, clinical 
requirement for coronary 
revascularization, life-
threatening arrhythmia in 
absence of implanted 
defibrillator, malignancy 
within 5 years of 
screening 
2 20 million, 
100 million, 
or 200 million 
mesenchymal 
stem cells 
 
OUTCOMES MEASURED 
 The outcomes measured were based on a Patient-Oriented Evidence that Matters 
(POEM).  This EBM review measured the outcome of improvement in quality of life in patients 
with cardiopathy that received stem cell injections.  Among the three review articles, quality of 
life was measured using either the Kansas City Cardiomyopathy Questionnaire (KCCQ) and/or 
the Minnesota Living with Heart Failure Questionnaire (MLHFQ).  The KCCQ is a twenty three 
questionnaire where a higher score indicated improvement in the quality of life.  The MLHFQ is 
a twenty-one questionnaire where a higher score indicated a decrease in quality of life.  
Questionnaires were given to patients at either three, six, and/or twelve months after stem cells 
or visually matched placebo injections. 
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RESULTS 
 Three RCT articles were compared and contrasted in this EBM review to determine if 
stem cell injections improve the quality of life in patients with cardiopathy diseases.  Due to the 
lack of RCTs and research trials, this EBM does not differentiate between bone marrow, 
umbilical derived G-CSF stem cells.  The focus of this EBM is about the improvement of quality 
in patients with cardiopathy diseases who received stem cell injections regardless of the origin of 
the stem cells.  Improvement in quality of life was assessed using the MLHFQ and/or the KCCQ. 
The MLHFQ is a 21-item self-administer questionnaire that evaluates the patient's 
improvement of quality of life by assessing the effects of heart failure on physical, 
socioeconomic and psychological aspects of life.12  Scores range from 0 to 105, where higher 
scores indicated a decrease in quality of life.  The KCCQ is a 23-item self-administer 
questionnaire that measured the quality of life by focusing on areas such as physical limitation, 
symptoms, social limitation, symptom stability and self-efficacy.13  Higher scores on the KCCQ 
indicated an improvement in quality of life. 
 In the study performed by Bartolucci et al, 65 patients were assessed for eligibility and 30 
were selected and randomized into two groups: treatment or placebo.  Eligibility inclusion 
criteria consist of but are not limited to patients with heart failure with a reduced ejection fraction 
(HFrEF) of < 40%  or a patient who meets the conditions of the New York Heart Association 
(NYHA) for classification I to III.12  Exclusion criteria consisted of patients with end-stage 
HFrEF or uncontrolled atrial fibrillation or ventricular tachycardia.12  A complete list of 
inclusion and exclusion criteria can be found in Table 1.  Patients were randomly assigned via a 
computer-generated list to a treatment or a placebo group by a person unrelated to the study.12     
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The control group in Bartolucci et al, received visually matched placebo injections while 
the treatment group received umbilical derived stem cell injections at 2mL/min via peripheral 
vein for 30 minutes on days 0, 15 and 90.12  Following completion of injections, all patients were 
assessed for quality of life at baseline, 3, 6 and 12 months with the MLHFQ and the KCCQ.  Out 
of the 15 patients in the placebo group, one patient was excluded from the data due to 
cardiovascular complication resulting in death. Another patient died due to unrelated 
complications. 
 The MLHFQ reported that the placebo group showed no significant mean change from 
baseline or a statistically significant p-value in the placebo group during any assessment 
periods.12  The treatment group for MLHFQ reported a statistically significant p-value less than 
0.05 at the 3 and 12 month assessment periods and a p-value less than 0.0167 in mean change 
from baseline at 6 months (Table 2).12  The placebo group in KCCQ stated a statistically 
significant p-value of < 0.05 at 3 and 6 months but not for 12 months in mean change from 
baseline.  The treatment group in KCCQ reported a p-value <0.05 in mean change from baseline 
at 3 and 6 months and a statistically significant p-value <0.0167 at 12 months in mean change 
from baseline (Table 2). 
Table 2: Comparison and statistically significant outcomes measured for MLHFQ and KCCQ 
Variable Group n Baseline 3 months 6 months 12 months 
MLHFQ Placebo 14 37.42±22.22 29.04±18.39 26.86±22.93 27.07±20.36 
 UC-MSC 14 53.21±30.25 30.50±23.76† 27.07±21.54* 31.21±26.66† 
KCCQ Placebo 14 69.92±21.24 78.08±15.94† 78.64±18.46† 75.46±22.43 
 UC-MSC 14 57.48±25.33 73.22±22.89† 74.99±20.70† 72.82±24.10* 
MLHFQ indicates Minnesota Living with Heart Failure Questionnaire; KCCQ indicates Kansas City 
Cardiomyopathy Questionnaire; UC-MSC indicates umbilical cord – mesenchymal stromal cells; *P<0.0167 vs 
baseline; †P<0.05 vs baseline. 
 
The data from both questionnaires reported statistically significant p-values of <0.05 or 
<0.0167 in treatment groups during all three assessment periods.  Overall, the data reported from 
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both questionnaires strongly suggest that stem cell injections improve the quality of life in 
patients with cardiopathy when compared to the placebo group. 
 In the Hamshere et al. study, 258 patients were assessed; 198 were excluded and 60 
patients were selected.14  Inclusion criteria for this study include but is not limited to left 
ventricular ejection fraction less than or equal to 45% and meets the NYHA classification II to 
IV.14  Exclusion criterion, less than 18 years old.   Additional inclusion criteria can be found in 
Table 1.  The 60 patients were randomized using a dedicated trial software system into four even 
groups of n = 15.  The three treatment groups received either G-CSF, G-CSF and intracoronary 
(IC) serum, or G-CSF and IC bone marrow-derived cells (BMCs).  The control group received 
visually matched placebo.  The three treatment groups received five days of G-CSF injections 
and all groups were assessed at baseline, three months and 12 months.  The data reported for the 
placebo and G-CSF treatment group decreased from n = 15 to n = 13 due to one patient 
withdrawal at the endpoint and another withdrawal at the 3-month assessment.  The G-CSF & IC 
serum treatment group reported 2 patients died after the 3-month assessment.  The G-CSF & IC 
BMC treatment group had one patient withdrawal and one patient declined the 1-year CT scan. 
 Significant p-values, listed in Table 3, were noted for the G-CSF group at both the 3- and 
12-month assessment.  No significant p-value were noted at either assessment point for the G-
CSF & IC serum group.  The lowest significant p-values calculated at both assessment points 
was for the G-CSF & IC BMC. The p-value for the 12-month assessment for the overall 
summary was 0.0053 and clinical summary noted a 0.0005 p value. 
Table 3: Quality of life assessment of group p-values for KCCQ overall and clinical summary 
 Placebo G-CSF G-CSF & IC 
Serum 
G-CSF & IC 
BMC 
KCCQ Overall Summary 
Baseline 53.39(-4.911-
9.680) 
50.80(37.48-
64.12) 
57.48(45.49-
69.47) 
42.29(29.20-
55.78) 
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P-value at 3 
months 
0.2947 0.0395 0.8435 0.0155 
P-value at 1 year 0.8526 0.0438 0.0679 0.0053 
KCCQ Clinical Summary 
Baseline  66.55(54.77-
78.32) 
60.41(47.21-
73.60) 
61.69(49.72-
73.66) 
21.25(33.36-
69.13) 
P-value at 3 
months 
0.7015 0.0555 0.8822 0.0028 
P-value at 1 year 0.4379 0.0592 0.0609 0.0005 
Values are mean (95% CI). EQ5D indicates European Quality of life – 5 dimensions; EQ5D  VAS indicates 
European Quality of life – 5 dimensions Visual analogue scale; KCCQ indicates Kansas City Cardiomyopathy 
Questionnaire.  
 
As expected, no improvement in quality of life was reported in the placebo groups.  The 
data reported at both assessment periods for the G-CSF and G-CSF & IC BMC treatment groups 
suggest strong evidence that an improvement in quality of life was noted in these patients.  
Therefore, the usage of G-CSF in combination with IC BMC demonstrated improvement in 
quality of life in patients with cardiopathy when compared to all other treatment groups and the 
controlled group.14 
 In the Hare et al. study, 96 patients were assessed for eligibility and only 31 were 
selected.8  An inclusion criterion for selection consisted of but is not limited to left ventricular 
ejection fraction less than 50%.  Exclusion criteria included malignancy within 5 years of 
screening or life-threatening arrhythmia.  Additional inclusion and exclusion criteria can be 
found in Table 1.  The eligible 31 patients were randomized into three groups of n = 10, 10 and 
11.  In this study, there is no control group and all three treatment groups received stem cell 
injections in three increasing dose of either 20 million, 100 million, or 200 million MSCs8.  The 
three treatment groups were further randomized and subdivided into two groups of either n = 5 or 
6 and were given autologous or allogeneic MSCs.  Autologous stem cells were derived from the 
iliac crest four to six weeks prior to stem cell injections.8  All treatment groups were injected 
once with the specific dose level at ten different sites in the heart.  The quality of life was 
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measured using the MLHFQ and was assessed at 6 and 12 months.8  Prior to the injection of 200 
million autologous MSCs, one patient was excluded from the data due to a left ventricular 
thrombus resulting in n = 5 in all subdivided treatment groups. 
 The results for the three different doses of MSCs for allogenic MSCs were combined and 
insignificant p-values of 0.29 and 0.34 were noted for the 6 month and 12-month assessment 
periods respectively.  Similarly, data from all groups that received autologous MSCs regardless 
of the dose level, reported statistically significant p-values of 0.005 at 6 months and a p-value of 
0.009 as at the 12-month assessment period (Table 4). 
Table 4: P-Value for MLHFQ for autologous vs. allogenic treatment groups 
 Baseline 6 Months 12 Months 
Autologous 43.6 (8.0) p-value = 0.005 p-value = 0.009 
Allogenic 38.9 (8.5) p-value = 0.29 p-value = 0.34 
95% CI; MLHFQ indicates Minnesota Living with Heart Failure Questionnaire. 
 Overall, the data consist of strong evidence that suggested stem cells, more specifically 
autologous than allogeneic stem cells, do improve cardiac function leading to an improvement in 
the quality of life in patients with cardiopathy. 
Safety, tolerability and adverse events 
 All patients tolerated UC-MSCs injections well and no adverse events, injuries, or 
hypersensitivity reaction was reported in the Bartolucci et al. study.  Similarly, no complications 
of G-CSF therapy injections were reported in the Hamshere et al. study.  A total of 7 patients 
(15.6%) did report long bone pain during therapy but this side effect was common and 
expected.14  As mentioned previously, two deaths were reported in the G-CSF and IC BMC 
group and both deaths were unrelated to the stem cell injections.  Hare et al. study reported that 
in one patient, cell culture became contaminated where bone marrow aspiration of autologous 
MSC had to be repeated.8 
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DISCUSSION 
 Depending on the severity, cardiopathy can severely influence a person’s quality of life 
by reducing a person’s ability to perform everyday activities.  Current treatments only delay the 
progression of heart failure and temporarily improve a patient’s quality of life.  Stem cells, on the 
other hand, have shown to improve cardiac function resulting in an improvement in the quality of 
life. 
 The objective of this EMB was to determine if stem cell injections, regardless of the 
origin of the stem cells, improve the quality of life in patients with cardiopathy.  All three studies 
used in this selective EBM review reported improvement in cardiac function resulting in an 
increase in quality of life.  Hare et al. study reported that the intervention of UC-MSC injections 
resulted in the improvement in left ventricular function resulting in an improvement in the 
quality of life in patients.8  Similarly, the Hamshere et al. study also reported that a combination 
of G-CSF with IC BMC demonstrated an improvement in cardiac function and symptoms 
resulting in an improvement in the quality of life.14  Improvement in quality of life with 
favorable improvement in functional capacity was also reported in Hare et al. study.8 
Limitations 
 Although stem cells were shown to be effective and safe in all three RCT articles, there 
are contraindications and limitations to stem cell injections.  One limitation is that stem cells 
have not been FDA approved.15  A major concern for the FDA about allogeneic stem cells 
injections is incompatibility resulting in an autoimmune reaction that could lead to complications 
such as death.16  Other limitations included cost, tumor formation, administration site reactions 
and the ability of stem cells to travel via the bloodstream and multiply in an undesirable 
location.10,15 
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 The three RCT studies also had limitations within their own study. The sample size for all 
three trials were small which could have possibly favor improvement in quality of life and the 
inclusion criteria was extensive resulting in lack of similar patient population.   The Bartolucci et 
al. study listed limitations such as software restraints, a response rate of 71% from the patients, 
and the large range of left ventricular volumes at baseline that could have favored the results of 
stem cell injections.12  
CONCLUSION 
 Base on the results of the three RCT articles, stem cell injections has shown to improve 
the quality of life in patients with cardiopathy.  The p-values reported were statistically 
significant indicating that the data reported did occur and is reliable.  Although all three articles 
did not use the same type of stem cells, those used showed improvement in cardiac function 
which led to an improvement in the quality of life. 
 Even with statistically significant p-values, the usage of stem cell therapy is relatively 
new and additional research should be performed.  The usage of similar stem cells in treatment 
groups should be unified to rule in the efficacy of one type of stem cell.  Although stem cell 
injections were reported safe and well received in all three RCTs, the possibility of rejection and 
the adverse effect will always be present.  If possible, future research can be performed on 
compatibility screening that limits rejection and immune response from the body.  Overall, stem 
cell injection therapy sounds promising but before approval, many limitations will have to be 
resolved. 
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